CPT2 and breast cancer: Similarly, studies have shown that knockdown of CPT2 or the use of FAO inhibitors in recurrent breast cancer significantly inhibited ERK expression and cell stemness in radiotherapy-resistant cells, thereby improving the efficacy of radiotherapy in recurrent breast cancer cells [122].